Benefit of Antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial

Cardiovascular Drugs and Therapy

Volumn 14, Issue 1, 2000, Pages 49-53

  Gasowski, Jerzy ^a   Birkenhäger, Willem H ^d   Staessen, Jan A ^a,c   De Leeuw, Peter W ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NONE

Author keywords

ACE inhibitors; Beta blockers; Diabetes; Dihydropiridine type long acting calcium channel blockers; Diuretics; Hypertension; Prospective antihypertensive trials; Trial endpoints

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; NISOLDIPINE; NITRENDIPINE; PLACEBO;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SHORT SURVEY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION;

EID: 0034051609     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007891121240     Document Type: Short Survey

References (23)

1. 1. Mehler PS, Jeffers BW, Estacio R, Schrier RW. Association of hypertension and complications in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997;10:152-161.
2. 2. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
3. 3. Curb JD, Pressel SL, Cutler JA, et al. for the Systolic Hypertension in the Elderly Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-1892.
4. 4. Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1999; 15(Suppl. 5):46S-51S.
5. 5. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340:677-684.
6. 6. Staessen JA, Fagard R, Thijs L, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
7. 7. Staessen JA, Thijs L, Fagard RH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998;32:404-409.
8. 8. Wang JG, Staessen JA, Gong L, Liu L for the Systolic Hypertension in China (Syst-China) Trial Investigators. Subgroup analysis of the placebo-controlled Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000 (in press).
9. 9. Sowers JR. Effects of calcium antagonists on insulin sensitivity and other metabolic parameters. Am J Cardiol 1997; 79:24-28.
10. 10. Ricciardelli B, Argenziano L, Morisco C, Monti F, Barbato E, Trimarco B. Effects of nitrendipine on plasma levels of insulin and glucose in patients with essential hypertension. Curr Ther Res 1997;58:180-186.
11. 11. Amery A, Birkenhäger W, Bulpitt C, et al. Diuretics - a risk in the long-term treatment of hypertensive patients? J Hypertens 1988;6:925-930.
12. 12. Epstein M. Calcium antagonists and renal protection. Current status and future perspectives. Arch Intern Med 1992; 152:1573-1584.
13. 13. Giugliano D, De Rosa N, Marfella R, et al. Comparison of nitrendipine and cilazapril in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1993;3:927-932.
14. 14. Goa KL, Sorkin EM. Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of hypertension. Drugs 1987;33: 123-155.
15. 15. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997;30: 1606-1612.
16. 16. Berkels R, Klaus W, Boller M, Roesen R. The calcium modulator nifedipine stimulates endothelial NO release in therapeutical concentrations. Pharm Pharmacol Lett 1996;6: 75-78.
17. 17. The HOT Study Group. The Hypertension Optimal Treatment Study (The HOT Study). Blood Press 1993;2:62-68.
18. 18. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.
19. 19. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
20. 20. Tatti P, Pahor M, Byington RB, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
21. 21. Epstein M. Calcium antagonists and renal disease. Kidney Int 1998;54:1771-1784.
22. 22. Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 1996;7:219-223.
23. 23. Parving HH, Rossing P. Diabetes and risk of adverse effects with calcium antagonists. Diabetes Care 1999;21:1179-1780.